FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an antibody against programmed cell death ligand-1 (hereinafter – PD-L1) that specifically binds PD-L1, as well as to an immunoconjugate and a composition containing it. A method for producing the above-mentioned antibody is also disclosed. The invention also relates to an isolated nucleic acid molecule encoding the antibody against PD-L1, as well as to a vector and a cell containing the above-mentioned molecule.
EFFECT: invention is effective for the detection of PD-L1 protein in a patient’s sample, as well as for the treatment of cancer in a subject.
36 cl, 22 dwg, 12 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| COMBINATION THERAPY OF ANTIBODY TO PROGASTRIN AND IMMUNOTHERAPY FOR CANCER TREATMENT | 2018 |
|
RU2784604C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| BISPECIFIC ANTIBODIES TO CCL2 | 2020 |
|
RU2819613C1 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
